Real-life EValuation Of High Dose RosUvastatin in High Risk Patients After TitraTION (REVORUTION)

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: September 5, 2007
Last updated: March 19, 2012
Last verified: March 2012
To evaluate achievement ratio of treatment target goal in hypercholesterolemia patients with high risk after high dose rosuvastatin(20mg/day) titration


Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: An Observational, Non-interventional, Multi-center Study to Evaluate Efficacy and Tolerability of High Dose Rosuvastatin in High Risk Patients After Titration

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Enrollment: 1482
Study Start Date: May 2007
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Hypercholesteromia patients with high risk according to NCEP ATP III guideline in Korean tertiary care centers

Inclusion Criteria:

  • High-risk hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on the physician's clinical decision and fulfill the following criteria

    1. Over 18 years of age
    2. Have history of CHD or CHD risk equivalents, such as peripheral arterial disease, abdominal aortic aneurysm, symptomatic carotid artery disease (TIA or stroke of carotid origin or >50% obstruction of carotid artery), DM, and 2+ risk factors with 10-year risk CHD>20%

Exclusion Criteria:

  1. Patients already taking other hyperlipidemic agents
  2. Patients who do not fulfil the indication criteria for statin therapy
  3. Patients who do not have baseline and/or follow-up lipid data to verify the efficacy data
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00526721

Korea, Republic of
Research Site
Seoul, Jongro-gu, Korea, Republic of
Research Site
Seoul, Kangnam-gu, Korea, Republic of
Research Site
Seoul, Songpa-gu, Korea, Republic of
Sponsors and Collaborators
Study Director: Hyunah Caroline Choi AstraZeneca Korea
  More Information

No publications provided

Responsible Party: AstraZeneca Identifier: NCT00526721     History of Changes
Other Study ID Numbers: NIS-CKR-CRE-2007/6
Study First Received: September 5, 2007
Last Updated: March 19, 2012
Health Authority: Korea:

Keywords provided by AstraZeneca:
LDL target goal
high risk patients

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases
Anticholesteremic Agents
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on November 27, 2015